Welcome to the Porton Newsroom
Porton Newsletter - Q1 2025 Recap
Technical Enabling
Services & Solutions
Company Events
ESG
Marketing Activities
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
DCAT Week 2025 — The Premier Event Connecting Biotech and Pharmaceutical Industries
DCAT Week is the premier annual event for the biotechnology and pharmaceutical manufacturing value chain. With senior decision-makers in attendance, it provides a unique platform for healthcare companies of all sizes to conduct high-level business meetings and foster strategic partnerships.
Porton Wins Outsourced Pharma 2025 CDMO Leadership Award
In March 2025, Porton Pharma Solutions Ltd. was honored with the "Global Small Molecule API Award" at the 14th Outsourced Pharma CDMO Leadership Awards, recognizing its exceptional end-to-end services across the global small molecule drug lifecycle. This award reaffirms Porton's outstanding performance in the CDMO sector for pharmaceutical R&D and manufacturing worldwide.
Porton Newsletter - Jan. to Feb. 2025 Recap
Technical Enabling
Technical Solutions for PROTAC Drugs
Successful GMP Drug Product Delivery by Porton Biologics and Conjugates Platform
Porton to Showcase Cutting-edge Innovations at BIO-Europe Spring 2025
Porton Pharma Solutions will once again participate in BIO-Europe Spring 2025, held from March 17th to 19th, at booth #87.
Join Porton at Leading Industry Conferences to Explore Innovations and Network with Experts
Porton Pharma Solutions is thrilled to announce its participation in several major industry events across the globe during the first and second quarters of 2025. As a leading end-to-end integrated CDMO company, Porton boasts globally advanced technology platforms and extensive project delivery experience in small molecules, peptides and oligonucleotides, ADCs (including antibodies, payload-linkers, conjugation, and drug product filling).
Our Incredible Journey in 2024
Under open skies, the years pass endlessly.
As the sun rises,
Porton welcomes a new year with sincerity and hope.
Reflecting on 2024,
we faced challenges together,
standing strong and united, achieving great heights.
Successful GMP Drug Product Delivery by Porton Biologics and Conjugates Platform
Recently, the Porton Biologics and Conjugates Platform successfully completed the GMP contract manufacturing of three batches of sterile drug products for a client at our R&D and production facility in Pudong, Shanghai. This milestone marks a significant step forward for our Biologics and Conjugates CDMO platform—a testament to our unwavering commitment to quality and reliability.
